| Uinta Spine Align | |
|
1425 Highway 150 S Ste 2, Evanston, WY 82930-5377 | |
| (307) 222-4322 | |
| (307) 444-4325 |
| Full Name | Uinta Spine Align |
|---|---|
| Type | Facility |
| Speciality | Chiropractor |
| Location | 1425 Highway 150 S Ste 2, Evanston, Wyoming |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104692375 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | (* (Not Available)) | Primary |
| Provider Name | Jay D Mangum |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1699127159 PECOS PAC ID: 3577891621 Enrollment ID: I20240202003362 |
News Archive
Gecko Biomedical, a French medical device company developing 'bio-inspired' biodegradable surgical glues and patches for wound closure, announces that the Company's co-founders have published data demonstrating the potential of its paradigm-shifting technologies for minimally invasive reconstructive heart surgery.
As part of a federal initiative to better understand traumatic brain injuries suffered by the nation's military service members and veterans, researchers at RTI International will join a consortium led by Virginia Commonwealth University to better understand the long-term effects of chronic mild brain injuries, or concussions.
Ranbaxy Laboratories Limited announced today that the Company has received approval from the U.S. Food and Drug Administration to manufacture and market Fenofibrate Capsules USP, 43 mg and 130 mg. The Office of Generic Drugs, U.S. Food and Drug Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Antara Capsules, 43 and 130 mg, respectively, of Lupin Atlantis.
Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has begun enrolling patients into the fourth dosage cohort in its Phase I clinical trial of its lead product candidate, BP-100.1.01 (Liposomal Grb-2), which is being evaluated as a systemic treatment for blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Uinta Spine Align 1425 Highway 150 S Ste 2, Evanston, WY 82930-5377 Ph: (307) 222-4322 | Uinta Spine Align 1425 Highway 150 S Ste 2, Evanston, WY 82930-5377 Ph: (307) 222-4322 |
News Archive
Gecko Biomedical, a French medical device company developing 'bio-inspired' biodegradable surgical glues and patches for wound closure, announces that the Company's co-founders have published data demonstrating the potential of its paradigm-shifting technologies for minimally invasive reconstructive heart surgery.
As part of a federal initiative to better understand traumatic brain injuries suffered by the nation's military service members and veterans, researchers at RTI International will join a consortium led by Virginia Commonwealth University to better understand the long-term effects of chronic mild brain injuries, or concussions.
Ranbaxy Laboratories Limited announced today that the Company has received approval from the U.S. Food and Drug Administration to manufacture and market Fenofibrate Capsules USP, 43 mg and 130 mg. The Office of Generic Drugs, U.S. Food and Drug Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Antara Capsules, 43 and 130 mg, respectively, of Lupin Atlantis.
Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has begun enrolling patients into the fourth dosage cohort in its Phase I clinical trial of its lead product candidate, BP-100.1.01 (Liposomal Grb-2), which is being evaluated as a systemic treatment for blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS).
› Verified 3 days ago
Davidson Chiropractic Clinic - Evanston Llc Chiropractor Medicare: Medicare Enrolled Practice Location: 195 Feather Way Ste A, Evanston, WY 82930 Phone: 307-382-0600 Fax: 307-382-0601 | |
Dr. Kenneth Casey Davis, D.C. Chiropractor Medicare: Medicare Enrolled Practice Location: 1101 Main Street, Suite 208, Evanston, WY 82930 Phone: 307-444-7773 | |
Dr. Dee Dillree, D.C. Chiropractor Medicare: Medicare Enrolled Practice Location: 1425 Highway 150 S, Ste 2, Evanston, WY 82930 Phone: 307-789-4957 Fax: 307-789-4959 | |
Dr. Zane Blazzard Dillree, DC Chiropractor Medicare: Medicare Enrolled Practice Location: 624 W Cheyenne Dr Ste 3, Evanston, WY 82930 Phone: 307-679-4429 Fax: 307-789-4959 | |
Evanston Chiropractic Center Inc. Chiropractor Medicare: Medicare Enrolled Practice Location: 624 W Cheyenne Dr Ste 3, Evanston, WY 82930 Phone: 307-679-4429 Fax: 307-789-4959 | |
Mr. Todd Eric Hoover, DC Chiropractor Medicare: May Accept Medicare Assignments Practice Location: 545 Cheyenne Dr, Suite A, Evanston, WY 82930 Phone: 307-789-0043 Fax: 307-789-0044 |